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Dear Editor,
Refractory agitation (RA) is a fre-
quent and challenging problem in
patients in the pediatric intensive care
unit (PICU). After exclusion of
imminent hypoxia, the differential
diagnosis of RA includes: (i) delirium
due to the underlying critical illness,
and/or (ii) withdrawal, and/or (iii)
disinhibition/paradoxical arousal due
to benzodiazepines [1, 2]. In most
cases, haloperidol gives satisfactory
results [3], although RA may persist
despite this treatment. Also benzodi-
azepines are often given, but may be
ineffective or even contraindicated to
restore patient comfort. After all,
many patients in a PICU already
receive or have received benzodiaze-
pines and may have developed a
certain level of tolerance. In others,
benzodiazepines should be avoided
because of associated disinhibition,
which has particularly been observed
in critically and/or terminally ill
children [2]. Therefore, a rescue
strategy may be needed [1].
A possible solution for the treat-
ment of RA is the addition of
methotrimeprazine (MTZ, also
known as levomepromazine or Noz-
inan), an aliphatic phenothiazine
neuroleptic drug with a weak anti-
psychotic, but strong sedative effect.
This classic neuroleptic is commonly
used as co-medication in emergency
psychiatry in adults to treat acute
psychosis or mania by reducing levels
of agitation, anger, and aggressive-
ness [4], thereby improving comfort
for all—the patient, family, and
members of the multidisciplinary
team. There is no literature to allow
for advisory dosages of MTZ in
children with RA; however, in palli-
ative care 0.1 mg/kg IV/SC/8 h is
suggested [1]. In adults, maximum
dosages of t.i.d. 25–50 mg/orally/
24 h MTZ are common. Potential, but
rare side effects of MTZ include tar-
dive dyskinesia, akathisia, neuroleptic
malignant syndrome, and extrapyra-
midal and cholinergically mediated
side effects; a contraindication is
bone marrow depression [4].
We recently used MTZ in four
critically ill children presenting with
RA (patient characteristics are sum-
marized in Table 1). All patients
initially received standard analgose-
dative treatment according to
consensus guidelines [5]. Two
patients developed delirium for which
an individually titrated dosage of
haloperidol remained insufﬁcient or
ineffective. A third patient suffered
from therapy-resistant agitation dur-
ing slowly weaning from sedation, for
which several analgosedatives were
Table 1 Patient characteristics
Patient
no.
Gender Age
(years)
Weight
(kg)
Mortality Medical condition PIM
score
PRISM
score
Initial therapy
for RA
Maximum rescue dosage
methotrimeprazine
1 Male 13 62 No Reduced consciousness
caused by increased
intracranial pressure,
due to pilocytic
astrocytoma in the third
ventricle
1.91 1.73 Haloperidol b.i.d. 6.25 mg orally
2 Male 5 19 No Postoperative closing
tracheostomy
1.12 1.12 Haloperidol t.i.d. 1 mg intravenously
3 Male 15 20
a Yes Respiratory insufﬁciency
due to a swollen tongue
17.14 0.42 Haloperidol
Ketamine
Benzodiazepines
Alimemazine
Apomorphine
Chloral hydrate
b.i.d. 10 mg enterally
4 Female 0.7 6.8 Yes Respiratory insufﬁciency
due to pulmonary
hypertension
3.97 6.08 Haloperidol
Ketamine
Benzodiazepines
Alimemazine
q.i.d. 1 mg intravenously
a Low body weight due to severe mental retardation and bedridden state based on pontocerebellar hypoplasia type 2
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patient experienced repeated periods
of agitation due to progressive pul-
monary hypertension, for which
amongst others haloperidol seemed
ineffective. In all cases, additional
intravenous or enteral administered
MTZ successfully reduced RA and
restored the comfort of the child and
everyone involved. No side effects
were observed. Long-term outcome
of our four patients varied: patients 3
and 4 were treated with MTZ in the
terminal phase of palliative care and
died peacefully, patient 2 did not
experience further agitation after
treatment, and patient 1 still receives
MTZ successfully.
We conclude that once RA still
continues after adequate 24-h dosages
of D2-blocking agents, the addition of
MTZ by trial and error titration might
be a useful option [4]. We would like
to reintroduce and underscore, on the
basis of empirical evidence and by
analogy to what is known in adults [1,
4], the use and effectiveness of MTZ
in the treatment of RA in critically ill
children in the PICU.
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